bioRxivNeurosciencePreprint
Pin1 Regulatory miRNAs as Novel Candidates for Alzheimer’s Disease Treatment
Elyas HeidariiD, Elham Salehi Siavashani, Mohammad Rasooli, Zahra AmiriiD, Ali Sharifi‐ZarchiiD, Koorosh ShahpasandiD
Abstract
Alzheimers disease (AD) is the sixth leading cause of death in elderly people whose pathological hallmarks include senile plaques and neurofibrillary tangles (NFTs). The tangles are composed of hyperphosphorylated tau, which is a microtubule-associated protein and its hyperphosphorylation would result in its aggregation and neural cell death. Recently, it has been shown that phosphorylated tau at Thr231 exists in two distinct cis & trans conformations, whose conversion is being mediated by Pin1 isomerase and that the cis, but not the trans, is extremely neurotoxic and drives tau hyperphosphorylation. It has been demonstrated that Pin1 inhibition reflects cis pT231-tau accumulation in neurons but its overactivation is observed in cancer stem cells. Hence, a precise Pin1 regulation is required to keep cells in healthy conditions. As miRNAs play a crucial role in fine-tuning of the gene-expression level, we hypothesized that they might regulate the Pin1 dosage. Nonetheless, the possible regulatory roles of miRNAs in progression of AD by regulating PIN1 is not well studied. We aimed to identify potential miRNAs that down-regulate PIN1 in AD. This can uncover new regulatory mechanisms that result in AD. Thus, we performed a comprehensive study of miRNAs, capable in regulating Pin1, through whole-genome meta-analysis by integrating miRNA expression profiles of 846 different biological samples, along with a systematic literature review and data mining of multiple experimental and predicted miRNA-target databases. We created a list of 56 candidates, which was then short-listed to 10 miRNAs with vigorous experimental evidence. We examined the expression patterns of these miRNAs in the AD and healthy controls and integrated mRNA and miRNA expression profiles to study possible interactions between miRNAs and Pin1. Moreover, we performed an in-silico functional analysis by integrating data of knock-in and knock-down experiments of the candidate miRNAs, and highlighted miR296-5p, miR200b, miR200c, miR140-5p, and miR874 as strong candidate Pin1 regulators. These findings would have profound implications in developing novel therapeutic strategies for AD by blocking expression of highlighted miRNAs using antagomirs.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- approach: experimental assay
- Citations
- 4
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MiR-219 deficiency in Alzheimer’s disease contributes to neurodegeneration and memory dysfunction through post-transcriptional regulation of tau-kinase network
Mercedes Arnés, Yoon A. Kim, … Ismael Santa‐María·bioRxiv·Apr 12, 2019
- MicroRNA-181 influences Alzheimer's risk by regulating neprilysin and microtubule-associated tau pathways, offering a novel target
Ruizhi Wang, Bryan Maloney, … Debomoy K. Lahiri·bioRxiv·Jun 16, 2026
- Rethinking Alzheimers: Novel miRNAs Illuminate a Disease Beyond the Brain
Jan Novotný, Mária E. Čarná, … Gorazd Bernard Stokin·Molecular PsychiatryPeer-reviewed·Feb 13, 2026
- Reduced PIN1 gene expression in neocortical and limbic brain regions in female Alzheimer's patients correlates with cognitive and neuropathological phenotypes
Camila de Ávila, Crystal Suazo, … Diego Mastroeni·bioRxiv·Aug 14, 2023
- Differential microRNA expression analyses across two brain regions in Alzheimer's disease
Valerija Dobričić, Marcel Schilling, … Lars Bertram·Translational PsychiatryPeer-reviewed·Aug 29, 2022
- Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer’s disease
Ellis Patrick, Sathyapriya Rajagopal, … Philip L. De Jager·Molecular NeurodegenerationPeer-reviewed·Jul 1, 2017